Waltham, Massachusetts, based Tesaro (NASDAQ:TSRO), is an oncology-focused biopharma company, which develops and commercializes effective therapeutics for cancer patients. The company aims to leverage its experience to identify, acquire, and develop promising drug candidates as well as commercialize them for the treatment of cancer patients. It in-licenses these products rather than perform in-house drug discovery. TSRO has seen a growth of more than 100% since the beginning of this year.
TSRO data by YCharts
The second-half of 2013 will be more important from investors' perspective, as I expect Tesaro's first Phase 3 data readout, that includes Rolapitant data for prevention of chemotherapy induced nausea and vomiting, or CINV. With Niraparib gaining more visibility as PARP inhibitor for...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|